NCT05763459View on ClinicalTrials.gov

A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

March 24, 2023

Primary Completion Date

May 8, 2023

Study Completion Date

June 2, 2023

Conditions

Healthy

Interventions

DRUG

ABBV-CLS-7262

Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin

Trial Locations (1)

60030

AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake

Sponsors

Lead Sponsor

Calico Life Sciences LLC

Collaborators (1)

All Listed Sponsors

collaborator

AbbVie

INDUSTRY

lead

Calico Life Sciences LLC

INDUSTRY